BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage develop…
Biotechnology
US, Palo Alto [HQ]
Ratios
7 Sheets · From 2023 to 2017Configuration
Margins, Growth Rates In %
| Ratio | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross Margin | - - | - - | 93.84 | 62.57 | 95.53 | 95.58 | 73.71 | |
| Profit Margin | - - | - - | -642.10 | -5,866.47 | -917.00 | -636.16 | -6,913.92 | |
| Operating Margin | - - | - - | -656.41 | -5,751.99 | -831.58 | -607.71 | -6,528.75 | |
|
EPS Growth
|
- - | -330.30 | -74.65 | -65.32 | -8.05 | 24.38 | -17.91 | |
| EPS USD | -33.00 | -142.00 | -248.00 | -410.00 | -443.00 | -335.00 | -395.00 | |
| Return on Assets (ROA) | -31.17 | -28.12 | -41.23 | -68.78 | -63.12 | -79.28 | -117.72 | |
| Return on Equity (ROE) | 52.68 | 79.73 | -63.76 | -835.71 | 73.45 | 39.37 | 47.49 | |
| Return on Invested Capital (ROIC) | 52.33 | 184.35 | -46.54 | -82.04 | -73.43 | -101.76 | -174.76 | |
| Solvency | ||||||||
| Equity Ratio | - - | - - | - - | - - | - - | -100 | -200 | |
| Debt/Assets | - - | 11.72 | 17.06 | 70.47 | 170.92 | 277.23 | 318.43 | |
| Debt/Equity | - - | -33.24 | 26.39 | 856.19 | -198.88 | -137.67 | -128.47 | |
| Debt/EBITDA | 209.94 | 208.54 | 94.48 | -29.80 | -246.89 | -380.82 | -237.35 | |
|
Debt/Capitalization
|
- - | -49.79 | 20.88 | 89.54 | 201.13 | 365.46 | 451.23 | |
| Long-Term Debt/Capitalization | - - | -49.79 | 19.63 | 89.51 | 201.71 | 367.54 | 455.03 | |
| Interest Debt per Share USD | - - | 0.62 | 1.11 | 4.51 | 12.32 | 12.26 | 11.19 | |
| Debt Growth | - - | - - | 83.08 | 396.83 | 248.17 | -0.15 | 0.94 | |
| Liquidity | ||||||||
| Current Ratio | 1,136.04 | 1,366.68 | 1,144.92 | 699.84 | 645.28 | 429.03 | 332.02 | |
| Quick Ratio | 1,075.96 | 1,338.63 | 1,042.27 | 660.94 | 658.12 | 415.28 | 303.55 | |
| Cash Ratio | 1,075.96 | 1,338.63 | 694.42 | 387.67 | 302.60 | 319.90 | 261.35 | |
| Operating Cash Flow Ratio | -400 | -400 | -400 | -400 | -300 | -300 | -300 | |
| Turnover | ||||||||
| Inventory Turnover | - - | - - | - - | - - | -4.52 | 9.05 | 14.69 | |
| Receivables Turnover | - - | - - | - - | - - | 353.01 | 454.64 | 531.30 | |
| Payables Turnover | - - | - - | 28.24 | 34.52 | 26.20 | 29.71 | 22.96 | |
|
Asset Turnover
|
- - | - - | 6.42 | 1.17 | 6.88 | 12.46 | 1.70 | |
| Fixed Turnover | - - | - - | 721.07 | 22.40 | 151.65 | 307.55 | 46.88 | |
| Coverage | ||||||||
| Interest Coverage | -337,369.23 | -7,210.84 | -3,037.54 | -1,294.45 | -1,239.36 | -586.63 | -747.17 | |
| Asset Coverage | - - | 700 | 500 | 100 | - - | - - | - - | |
| Cash Flow Coverage (CFGR) | - - | -250.69 | -235.26 | -80.62 | -28.76 | -24.29 | -30.33 | |
| EBITDA Coverage | -337,000 | -7,100 | -3,100 | -1,200 | -1,100 | -400 | -700 | |
| Dividend Coverage | 2,600 | - - | 26,100 | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||||
| Dividend Yield | 0.05 | - - | 0.03 | - - | - - | - - | - - | |
| Earnings Yield | -1.20 | -5.14 | -7.07 | -5.77 | -26.55 | -43.96 | -9.79 | |
|
Price/Earnings (P/E)
|
-8,322.24 | -1,945.48 | -1,414.44 | -1,733.88 | -376.64 | -227.50 | -1,021.75 | |
| Price/Earnings Growth (PEG) | - - | -5.89 | -18.95 | -26.54 | -46.80 | 9.33 | -57.05 | |
|
Price/Book (P/B)
|
-4,384.47 | -1,551.17 | 901.87 | 14,490.13 | -276.63 | -89.57 | -485.28 | |
| Price/Tangible Book (P/TB) | -4,384.47 | -1,551.17 | 901.87 | 14,490.13 | -276.63 | -89.57 | -485.28 | |
| Price/Sales (P/S) | - - | - - | 9,082.16 | 101,717.26 | 3,453.82 | 1,447.23 | 70,642.73 | |
|
Price/Cash Flow (P/CF)
|
-6,282.59 | -1,861.56 | -1,452.65 | -2,099.17 | -483.57 | -267.88 | -1,245.34 | |
| Price/Free CF (P/FCF) | -6,211.40 | -1,642.99 | -1,423.80 | -2,060.41 | -440.86 | -263.90 | -1,242.26 | |
| Price/Operating CF (P/OCF) | -6,282.59 | -1,861.56 | -1,452.65 | -2,099.17 | -483.57 | -267.88 | -1,245.34 |